At its meeting today (25 September 2024) NICE’s Board concluded the new severity modifier is working as intended and is ...

10395 - Aprocitentan for treating resistant hypertension TS ID 10395 Technology appraisal guidance Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 Technology appraisal ...

As NICE celebrates its 25th anniversary, I thought I’d highlight one of the organisation’s most long-standing collaborative ...

Evidence from current practice provided by NHS England and analysed by NICE indicates that digital therapies recommended for PTSD could save over 5,000 hours of therapist time per 1,000 people. Almost ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

There is a simple discount patient access scheme for rucaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible to be a stakeholder? Contact the stakeholder ...

A list of downloadable documents created during development.

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.